NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis $101.50 +0.52 (+0.52%) As of 09:36 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lantheus Stock (NASDAQ:LNTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lantheus alerts:Sign Up Key Stats Today's Range$100.98▼$100.9850-Day Range$73.09▼$103.0052-Week Range$47.25▼$104.00Volume342 shsAverage Volume951,385 shsMarket Capitalization$6.61 billionP/E Ratio24.48Dividend YieldN/APrice Target$101.86Consensus RatingModerate Buy Company Overview Lantheus Holdings, Inc. is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications. The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow. On the molecular imaging side, Lantheus markets Cardiolite® (technetium Tc-99m sestamibi) for myocardial perfusion imaging and Lexiscan® (regadenoson) for pharmacologic stress testing. In 2021, the company gained FDA approval and launched PYLARIFY® (piflufolastat F 18), a PET imaging agent for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Lantheus also maintains a robust pipeline of next-generation PET and therapeutic candidates in collaboration with academic and industry partners. Founded in 1956, Lantheus has expanded its reach through strategic acquisitions and global partnerships, serving hospitals, imaging centers and research institutions in more than 50 countries. The company operates a network of manufacturing facilities across North America and Europe, adhering to stringent quality and regulatory standards. Lantheus’ leadership team comprises experienced executives from the pharmaceutical and medical imaging industries, guiding the organization’s growth in precision diagnostics and targeted radiopharmaceutical therapies. Continuous investment in research and development underpins Lantheus’ mission to deliver innovative solutions that improve patient outcomes and drive value for healthcare providers worldwide.AI Generated. May Contain Errors. Read More Lantheus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreLNTH MarketRank™: Lantheus scored higher than 43% of companies evaluated by MarketBeat, and ranked 604th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Lantheus is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageLantheus has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lantheus' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth22.17% Earnings GrowthEarnings for Lantheus are expected to grow by 22.17% in the coming year, from $4.42 to $5.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 24.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 24.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.85.Price to Book Value per Share RatioLantheus has a P/B Ratio of 6.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.06% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.84.Change versus previous monthShort interest in Lantheus has recently increased by 13.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.54 News SentimentLantheus has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lantheus this week, compared to 11 articles on an average week.MarketBeat Follows4 people have added Lantheus to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LNTH Stock News HeadlinesAssessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price GainsJune 5 at 5:14 PM | finance.yahoo.comLantheus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 3, 2026 | globenewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.June 8 at 1:00 AM | Brownstone Research (Ad)Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the YearJune 2, 2026 | markets.businessinsider.comLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the YearJune 2, 2026 | globenewswire.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 29, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: IQVIA Holdings (IQV), Lantheus (LNTH)May 27, 2026 | theglobeandmail.comLantheus to Present at the William Blair 46th Annual Growth Stock ConferenceMay 27, 2026 | globenewswire.comSee More Headlines LNTH Stock Analysis - Frequently Asked Questions How have LNTH shares performed this year? Lantheus' stock was trading at $66.55 on January 1st, 2026. Since then, LNTH stock has increased by 51.7% and is now trading at $100.98. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its quarterly earnings data on Thursday, May, 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.25 by $0.21. The firm's quarterly revenue was up 1.2% on a year-over-year basis. Read the conference call transcript. When did Lantheus IPO? Lantheus (LNTH) raised $103 million in an IPO on Thursday, June 25th 2015. The company issued 10,833,334 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Top institutional shareholders of Lantheus include Janus Henderson Group PLC (7.33%), Dimensional Fund Advisors LP (2.12%), Epoch Investment Partners Inc. (1.00%) and Healthcare of Ontario Pension Plan Trust Fund (0.92%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Farallon Partners L L C/Ca, Rajiv A Patel, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Andrea Sabens, James H Thrall, Heinz Christoph Maeusli, Gerard Ber and Gary J Pruden. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today6/08/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 LNTH's financial health is in the Green zone, according to TradeSmith. LNTH has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNTH CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees1,193Year FoundedN/APrice Target and Rating Average Price Target for Lantheus$101.86 High Price Target$115.00 Low Price Target$80.00 Potential Upside/Downside+0.9%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$4.15 Trailing P/E Ratio24.33 Forward P/E Ratio22.85 P/E GrowthN/ANet Income$233.56 million Net Margins18.05% Pretax Margin24.17% Return on Equity29.32% Return on Assets15.00% Debt Debt-to-Equity Ratio0.47 Current Ratio2.83 Quick Ratio2.64 Sales & Book Value Annual Sales$1.55 billion Price / Sales4.25 Cash Flow$6.39 per share Price / Cash Flow15.81 Book Value$16.43 per share Price / Book6.15Miscellaneous Outstanding Shares65,106,000Free Float63,999,000Market Cap$6.57 billion OptionableOptionable Beta-0.03 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:LNTH) was last updated on 6/8/2026 by MarketBeat.com Staff. From Our PartnersThe "hidden" half of the SpaceX IPOMost investors are focused on the SpaceX IPO - but the bigger opportunity may lie elsewhere. On Feb. 2, Elon M...Weiss Ratings | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredMissed Nvidia’s 44,000%? This is the next big opportunityIn February 2016, Nvidia was trading at $2.51 split-adjusted - and a specific data pattern had already flagged...InvestorPlace | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredHit your retirement income goal with 10X less moneyFinancial advisors say you need $1.5 million to generate $5,000 a month in retirement. A newer investment cate...Investors Alley | SponsoredBNZI Breakout Watch: AI Growth Meets Turnaround Setup!Banzai International (NASDAQ: BNZI) posted full-year 2025 revenue of $12.2 million, up 169% year-over-year, wi...Huge Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
